Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458221 | 0.91 | PKM (0.43) | PKMNOTUMCYP11B1CYP11B2AGTR1 | |
| SCHEMBL22927013 | 0.89 | NPC1 (0.43) | KMT2A | |
| SCHEMBL26602340 | 0.85 | PKM (0.45) | PKMNOTUMCYP11B1CYP11B2AGTR1 | |
| SCHEMBL21458296 | 0.83 | NPC1 (0.42) | CYP11B1CYP11B2KMT2ATHRB | |
| SCHEMBL26606926 | 0.81 | EGLN1 (0.41) | EGLN1KMT2A | |
| SCHEMBL21506595 | 0.79 | PTGER4 (0.39) | EGLN1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL26602346 | 0.79 | NPC1 (0.44) | KMT2ATHRB | |
| SCHEMBL21506594 | 0.79 | ALDH1A1 (0.39) | EGLN1HCRTR1HCRTR2 | |
| SCHEMBL26606876 | 0.77 | TNF (0.37) | CYP11B1CYP11B2EGLN1HSP90AA1HSP90B1 | |
| SCHEMBL21506516 | 0.74 | PKM (0.43) | PKMNOTUMRHEBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-3781550-B1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| CN-112313208-B | Bicyclic carboxamides and methods of use thereof | 泰普斯特医疗公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11472789-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| CN-112313208-A | Bicyclic carboxamides and methods of use thereof | 泰普斯特医疗公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| WO-2019204523-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | PKM 1746/4885NOTUM 1291/4885CYP11B1 1017/4885 |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | PKM 1746/4885NOTUM 1291/4885CYP11B1 1017/4885 |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | PKM 1746/4885NOTUM 1291/4885CYP11B1 1017/4885 |
| US-11472789-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | PKM 1746/4885NOTUM 1291/4885CYP11B1 1017/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | PKM 1746/4885NOTUM 1291/4885CYP11B1 1017/4885 |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | PKM 1746/4885NOTUM 1291/4885CYP11B1 1017/4885 |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | PKM 1746/4885NOTUM 1291/4885CYP11B1 1017/4885 |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | PKM 1746/4885NOTUM 1291/4885CYP11B1 1017/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | PKM 1746/4885NOTUM 1291/4885CYP11B1 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.